Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna’s phase 1 data looks positive, but the company’s investigational coronavirus vaccine has a lot more to prove in late-stage trials.

Is Moderna Close to Winning the Coronavirus Vaccine Race?

BioNTech SE

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna, Sanofi and Johnson & Johnson and biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines - sources

The company's preparing to ship a product that hasn't even begun late-stage testing.

Why Is Moderna Already Making Coronavirus Vaccine Doses?

Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Moderna (MRNA) in Focus: Stock Moves 6.9% Higher

American Airlines

Beyond Meat

AstraZeneca

Unilever

Moderna, UnitedHeath, Beyond Meat, American Airlines and AstraZeneca were our top stock trades from Wednesday -- and here's why.

5 Top Stock Trades for Thursday: MRNA, AZN, AAL, BYND, UNH

Wall Street was licking its chops soon after Tuesday's closing bell, thanks to more positive news about

Stock Market Today: Moderna's Vaccine Progress Pumps Up the Market

The biotech shared some exciting news with investors.

Moderna Stock Soars on Promising Coronavirus Vaccine Trial News

The Dow posted a four-day winning streak.

Dow Jumps Over 200 Points After Moderna’s Coronavirus Vaccine News

Fortunately, the full data may not be required to get the vaccine on the market.

Full Results From Moderna's Coronavirus Vaccine Study Will Take 2 Years, at Least

Bloomin' Brands

Denny's

Brinker International

Gilead Sciences

Pfizer

Ruth's Hospitality Group

Chains such as Outback Steakhouse, Chili's, Denny's, and Ruth's Chris were climbing on a positive vaccine trial.

Why Casual Dining Restaurant Stocks Were Gaining Today

Moderna reported positive Phase I testing results for its COVID-19 vaccine, and will begin Phase III testing it on 30,000 humans in two weeks.

Moderna is testing a COVID vaccine on humans. This is what they’re not telling you

VanEck Vectors Biotech ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

SPDR S&P Biotech ETF

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

The now familiar group of reopening stocks – cruises, energy, hotels, airlines, retail etc. – are surging on vaccine hopes.

Moderna Vaccine Data Spurs Stock Market Rally

Eli Lilly

Johnson & Johnson

After a few years hanging out quietly on the sidelines, the Health Care sector roared back to prominence this year as COVID-19 ravaged the globe. Suddenly, vaccines and antibodies catapulted into the headlines, drawing attention to biotech and pharma amid a race to treat or prevent the virus.

GILDing” The Lilly: Vaccines, Treatments For Virus In Spotlight Ahead Of Health Care Q2 Earnings

Inovio Pharmaceuticals

The stock market moved higher Wednesday morning on optimism about a potential solution to the COVID-19 pandemic.

Nasdaq Rises on Moderna Coronavirus Vaccine Hopes -- at Inovio's Expense

BioCryst Pharmaceuticals

BioCryst’s moonshot probably won’t be as good for shareholders as Moderna’s has already been.

Better Buy: Moderna vs. BioCryst Pharmaceuticals

The company is one of the leaders in the COVID-19 vaccine race. Could its returns be massive?

Could Moderna's Coronavirus Vaccine Be a $5 Billion Opportunity?

Jim Cramer discussed trial data from Moderna's Covid-19 vaccine candidate, saying he wants to see information about insider stock sales before deciding how confident to be.

Cramer says he wants to see if Moderna execs sell stock before believing early vaccine developments

Vaxart

Both Moderna and Vaxart are expecting data readouts that will send the stocks skyrocketing -- if the news is positive.

These 2 Coronavirus Stocks Could Soar in the Second Half of 2020

Moderna Inc's shares rose around 11% on Wednesday after a small-scale study showed its experimental COVID-19 vaccine produced high levels of virus-killing antibodies, bolstering hopes the shot could prove effective in later stages of testing.

Moderna shares jump on data from early coronavirus vaccine trial

Moderna Inc. (NASDAQ: MRNA) made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.

Moderna’s Next Big Step in the Race to a COVID-19 Vaccine

Moderna Inc (NASDAQ: MRNA) shares awere bulldozing their way toward  record highs Wednesday in reaction to the publication in the New England Journal of Medicine of detailed interim Phase 1 data for mRNA-1273, its SARS-CoV2 vaccine candidate.

Moderna Analysts See Positives In Coronavirus Readout As Focus Shifts To Pivotal Phase 3 Study

Moderna's stock surged early Wednesday after the biotech company said its potential coronavirus vaccine generated a promising immune response in an early-stage human trial.

Moderna stock surges after releasing promising coronavirus vaccine trial data

Anthony Fauci does not know whether Moderna or Oxford/AstraZeneca will win the race for the first Covid-19 vaccine. The results of their Phase III trials will provide more clarity.

Will Moderna Beat Oxford To Produce The First Covid-19 Vaccine?

Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

News for Moderna Stock (MRNA)